Secondary Logo

Institutional members access full text with Ovid®

The rationality of combining second-generation antiandrogens with 177Lu-PSMA or its alpha-emitting congeners for better and durable results

will this dominate the therapeutic landscape and be an upfront consideration in metastatic castration-resistant prostate cancer in the coming years?

Basu, Sandipa,c; Parghane, Rahul V.a,c; Joshi, Amitb,c; Prabhash, Kumarb,c; Banerjee, Sharmilaa,c

doi: 10.1097/MNM.0000000000000932

aRadiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe

bDepartment of Medical Oncology, Tata Memorial Hospital

cHomi Bhabha National Institute, Mumbai, India

Correspondence to Sandip Basu, MBBS(Hons), DRM, DNB, MNAMS, Radiation Medicine Centre (BARC), Tata Memorial Hospital Annexe, Jerbai Wadia Road, Parel, Mumbai 400012, India Tel: +91 222 414 9428; fax: +91 222 415 7098; e-mail:

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.